Rituximab in cutaneous B-cell lymphoma: a report of two cases.

Abstract

We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphoma, which had undergone high-grade transformation and systemic spread, achieved a minor response of approximately 30%. Both patients subsequently relapsed. The first patient achieved complete clearance with a second course of rituximab given with systemic chemotherapy, but again relapsed. Treatment with rituximab has been reported to produce response rates of 48% in relapsed systemic low-grade or follicular lymphoma, but there are no previous reports of the use of rituximab in primary cutaneous B-cell lymphoma.

Statistics

0200400600'03'05'07'09'11'13'15'17
Citations per Year

433 Citations

Semantic Scholar estimates that this publication has 433 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Sabroe2000RituximabIC, title={Rituximab in cutaneous B-cell lymphoma: a report of two cases.}, author={Ruth A Sabroe and Fiona J Child and Alison J-A Woolford and Margaret F. Spittle and Robin J Russell-Jones}, journal={The British journal of dermatology}, year={2000}, volume={143 1}, pages={157-61} }